US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Health in Tech

0.9600

-0.0200-2.04%

Post-market: 0.96000.00000.00%19:41 EDT

Volume:46.42K

Turnover:45.13K

Market Cap:62.91M

PE:-14.70

High:0.9899

Open:0.9800

Low:0.9600

Close:0.9800

52wk High:4.02

52wk Low:0.8501

Shares:65.53M

Float Shares:20.30M

Volume Ratio:1.31

T/O Rate:0.23%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0653

EPS(LYR):0.0200

ROE:-21.91%

ROA:-12.72%

PB:3.22

PE(LYR):48.00

Loading ...

Overview Company News Filings

Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026

Health In Tech Files $300 Million Mixed Shelf Registration

MT Newswires Live

Health In Tech files $300M mixed securities shelf

Health in Tech - May Offer up to $300 Mln in Common Stock, Preferred Stock, Warrants, Debt, Rights, and Units - SEC Filing

THOMSON REUTERS

Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event

Yantian International, Chengdu Land Port Company, and HIT Sign Cooperation Agreement

One-Year Milestone for Chengdu-Shenzhen-Hong Kong Scheduled Rail Service: Fostering Trilateral Synergy and Bolstering the Real Economy

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

Health In Tech Inc reports results for the quarter ended March 31 - Earnings Summary

Health In Tech reports Q1 EPS (3c), consensus (2c)

Health In Tech backs FY26 revenue view $45M-$50M, consensus $46.36M

Health In Tech Q1 EPS $(0.03), Inline, Sales $4.509M Miss $7.349M Estimate

Benzinga Earnings

Health In Tech Q1 FY26 turns to net loss of $1.6 million; revenue rises 9.4% to $8.8 million

Press Release: Health In Tech Reports First Quarter 2026 Financial Results

Health In Tech Inc expected to post a loss of 3 cents a share - Earnings Preview

Press Release: Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA

Health in Tech AI, marketing chief Dustin Plantholt departs amid business transition

Health In Tech to report first-quarter results after market close May 13

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

Health In Tech files to sell 5.6M shares of Class A common stock for holders

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/HIT/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"HIT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIT\",,,,,undefined,":{"symbol":"HIT","market":"US","secType":"STK","nameCN":"Health in Tech","latestPrice":0.96,"timestamp":1788206400000,"preClose":0.98,"halted":0,"volume":46419,"hourTrading":{"tag":"盘后","latestPrice":0.96,"preClose":0.96,"latestTime":"19:41 EDT","volume":11,"amount":10.6002,"timestamp":1788219684879,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.02040816326530614,"floatShares":20299100,"shares":65529600,"eps":-0.0653,"marketStatus":"Closed","change":-0.02,"latestTime":"08-31 16:00:00 EDT","open":0.98,"high":0.9899,"low":0.96,"amount":45133.889985,"amplitude":0.03051,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0653,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788249600000},"marketStatusCode":5,"adr":0,"listingDate":1734930000000,"exchange":"NASDAQ","adjPreClose":0.98,"preHourTrading":{"tag":"盘前","latestPrice":0.96,"preClose":0.98,"latestTime":"08:12 EDT","volume":1,"amount":0.96,"timestamp":1788178328138,"change":-0.02,"changeRate":-0.020408,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.96,"preClose":0.96,"latestTime":"19:41 EDT","volume":11,"amount":10.6002,"timestamp":1788219684879,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.308145},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"HIT\",,,,,undefined,":{"symbol":"HIT","floatShares":20299100,"roa":"-12.72%","roe":"-21.91%","lyrEps":0.02,"volumeRatio":1.308145,"shares":65529600,"dividePrice":0,"high":0.9899,"amplitude":0.03051,"preClose":0.98,"low":0.96,"week52Low":0.8501,"pbRate":"3.22","psRate":"1.92","week52High":4.02,"institutionHeld":0,"latestPrice":0.96,"eps":-0.0653,"divideRate":0,"volume":46419,"delay":0,"ttmEps":-0.0653,"open":0.98,"prevYearClose":1.59,"prevWeekClose":0.98,"prevMonthClose":1.11,"prevQuarterClose":1.01,"fiveDayClose":0.97,"twentyDayClose":1.14,"sixtyDayClose":1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/HIT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"HIT","fiscalQuarterEnding":"2026/06","expectedEps":-0.03,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"post","actualEps":-0.04},{"market":"US","date":"2026-05-13","symbol":"HIT","fiscalQuarterEnding":"2026/03","expectedEps":-0.04,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1778644800000,"reportTimeType":"post","actualEps":-0.03},{"market":"US","date":"2026-03-25","symbol":"HIT","fiscalQuarterEnding":"2025/12","expectedEps":-0.01,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1774411200000,"reportTimeType":"post","actualEps":-0.01},{"market":"US","date":"2025-04-14","symbol":"HIT","fiscalQuarterEnding":"2025/03","expectedEps":0.02,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1744603200000,"reportTimeType":"post","actualEps":0.01}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"HIT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"HIT\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1778990400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/HIT\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"HIT","date":"2026-08-28","current":-14.701378,"percent":0.162291,"low":-99.750333,"twenty":31.190138,"median":58.057586,"eighty":125.359524,"high":221.999544,"avg":59.322618,"sd":77.05829,"marketCap":65547764},"quantilePoints":[{"date":"2024-12-27","current":157.125683,"twenty":141.889253,"median":160.399135,"eighty":163.672587,"marketCap":285486210},{"date":"2025-01-03","current":155.340164,"twenty":156.054372,"median":159.431979,"eighty":163.196448,"marketCap":282242048},{"date":"2025-01-10","current":163.077413,"twenty":154.387887,"median":159.134392,"eighty":162.958378,"marketCap":296300081},{"date":"2025-01-17","current":169.029144,"twenty":154.625956,"median":159.506375,"eighty":163.672587,"marketCap":307113953},{"date":"2025-01-24","current":153.257058,"twenty":154.447404,"median":161.291894,"eighty":169.029144,"marketCap":278457193},{"date":"2025-01-31","current":183.90847,"twenty":154.447404,"median":161.887067,"eighty":169.624317,"marketCap":334148632},{"date":"2025-02-07","current":158.018442,"twenty":154.447404,"median":161.291894,"eighty":169.029144,"marketCap":287108290},{"date":"2025-02-14","current":176.766393,"twenty":155.340164,"median":162.779827,"eighty":171.409836,"marketCap":321171986},{"date":"2025-02-21","current":200.275728,"twenty":156.768579,"median":163.672587,"eighty":173.909563,"marketCap":363886779},{"date":"2025-02-28","current":207.417805,"twenty":157.83989,"median":165.458105,"eighty":181.765847,"marketCap":376863425},{"date":"2025-03-07","current":212.774362,"twenty":158.73265,"median":167.690004,"eighty":197.061793,"marketCap":386595909},{"date":"2025-03-14","current":32.734517,"twenty":157.83989,"median":169.029144,"eighty":199.323452,"marketCap":59476293},{"date":"2025-03-21","current":56.458248,"twenty":154.030783,"median":165.606898,"eighty":197.656967,"marketCap":37853957},{"date":"2025-03-28","current":55.854885,"twenty":145.69836,"median":163.672587,"eighty":197.061793,"marketCap":37449416},{"date":"2025-04-04","current":54.649326,"twenty":57.938837,"median":162.779827,"eighty":197.002276,"marketCap":36641116},{"date":"2025-04-11","current":52.572179,"twenty":55.748991,"median":161.291894,"eighty":191.050546,"marketCap":35248437},{"date":"2025-04-17","current":34.087191,"twenty":54.660513,"median":159.506375,"eighty":186.170128,"marketCap":36423288},{"date":"2025-04-25","current":33.769958,"twenty":52.396232,"median":159.134392,"eighty":182.301503,"marketCap":36084314},{"date":"2025-05-02","current":31.160461,"twenty":45.578303,"median":157.125683,"eighty":179.087568,"marketCap":33295981},{"date":"2025-05-09","current":39.930417,"twenty":35.548508,"median":154.298611,"eighty":177.659153,"marketCap":42666968},{"date":"2025-05-16","current":34.281623,"twenty":35.548508,"median":153.257058,"eighty":177.123497,"marketCap":36631046},{"date":"2025-05-23","current":33.258292,"twenty":34.731889,"median":135.699453,"eighty":174.62377,"marketCap":35537582},{"date":"2025-05-30","current":33.427142,"twenty":34.164964,"median":62.92533,"eighty":173.07632,"marketCap":35718004},{"date":"2025-06-06","current":32.245193,"twenty":33.613388,"median":57.019717,"eighty":172.302595,"marketCap":34455053},{"date":"2025-06-13","current":30.699962,"twenty":33.084325,"median":56.156566,"eighty":171.409836,"marketCap":32803922},{"date":"2025-06-20","current":30.699962,"twenty":32.521493,"median":55.626806,"eighty":171.290801,"marketCap":32803922},{"date":"2025-06-27","current":40.953749,"twenty":32.521493,"median":54.649326,"eighty":170.576594,"marketCap":43760432},{"date":"2025-07-03","current":43.537662,"twenty":32.644293,"median":53.403037,"eighty":169.624317,"marketCap":46521429},{"date":"2025-07-11","current":56.794929,"twenty":32.734517,"median":52.352245,"eighty":169.029144,"marketCap":60687256},{"date":"2025-07-18","current":61.399923,"twenty":33.002459,"median":53.724933,"eighty":166.350865,"marketCap":65607844},{"date":"2025-07-25","current":80.355571,"twenty":33.207125,"median":54.437195,"eighty":165.755692,"marketCap":109376548},{"date":"2025-08-01","current":85.740222,"twenty":33.258292,"median":55.423164,"eighty":165.458105,"marketCap":116705904},{"date":"2025-08-08","current":95.681118,"twenty":33.427142,"median":55.842666,"eighty":164.267759,"marketCap":130237023},{"date":"2025-08-15","current":134.225003,"twenty":33.509008,"median":56.458248,"eighty":163.672587,"marketCap":182701302},{"date":"2025-08-22","current":141.681948,"twenty":33.769958,"median":56.907323,"eighty":163.672587,"marketCap":192851375},{"date":"2025-08-29","current":115.996916,"twenty":33.826241,"median":58.296911,"eighty":163.077413,"marketCap":157890014},{"date":"2025-09-05","current":116.411191,"twenty":33.871267,"median":61.399923,"eighty":162.601275,"marketCap":158453907},{"date":"2025-09-12","current":115.582641,"twenty":33.960297,"median":65.505359,"eighty":162.006102,"marketCap":157326121},{"date":"2025-09-19","current":146.238969,"twenty":34.065701,"median":68.343655,"eighty":161.410929,"marketCap":199054197},{"date":"2025-09-26","current":136.296377,"twenty":34.242737,"median":75.592225,"eighty":161.291894,"marketCap":185520767},{"date":"2025-10-03","current":145.41042,"twenty":34.400329,"median":82.840795,"eighty":159.863479,"marketCap":197926411},{"date":"2025-10-10","current":142.510497,"twenty":34.597833,"median":90.503568,"eighty":159.506375,"marketCap":193979161},{"date":"2025-10-17","current":142.096223,"twenty":34.762589,"median":102.722585,"eighty":159.387341,"marketCap":193415268},{"date":"2025-10-24","current":124.28241,"twenty":34.80557,"median":108.747109,"eighty":159.000478,"marketCap":169167873},{"date":"2025-10-31","current":108.125697,"twenty":35.001026,"median":110.197071,"eighty":158.196994,"marketCap":147176049},{"date":"2025-11-07","current":115.996916,"twenty":35.126896,"median":111.232757,"eighty":157.304235,"marketCap":157890014},{"date":"2025-11-14","current":65.041128,"twenty":35.682565,"median":110.611345,"eighty":156.370386,"marketCap":88531186},{"date":"2025-11-21","current":49.494631,"twenty":36.438807,"median":109.575659,"eighty":155.508444,"marketCap":71136010},{"date":"2025-11-28","current":60.185471,"twenty":37.969712,"median":108.125697,"eighty":154.804508,"marketCap":86501388},{"date":"2025-12-05","current":50.286545,"twenty":39.123499,"median":102.722585,"eighty":154.268852,"marketCap":72274186},{"date":"2025-12-12","current":41.971447,"twenty":39.670818,"median":90.503568,"eighty":153.792714,"marketCap":60323336},{"date":"2025-12-19","current":53.850158,"twenty":40.532136,"median":85.740222,"eighty":153.376093,"marketCap":77395978},{"date":"2025-12-26","current":60.185471,"twenty":40.941469,"median":80.355571,"eighty":152.899954,"marketCap":86501388},{"date":"2026-01-02","current":62.95717,"twenty":41.131809,"median":75.81227,"eighty":152.364298,"marketCap":90485004},{"date":"2026-01-09","current":63.353127,"twenty":41.869528,"median":71.272268,"eighty":151.636362,"marketCap":91054092},{"date":"2026-01-16","current":55.433987,"twenty":41.971447,"median":68.343655,"eighty":148.393197,"marketCap":79672331},{"date":"2026-01-23","current":58.601643,"twenty":41.971447,"median":67.881746,"eighty":147.067519,"marketCap":84225035},{"date":"2026-01-30","current":47.118888,"twenty":41.971447,"median":66.520784,"eighty":146.238969,"marketCap":67721481},{"date":"2026-02-06","current":39.591745,"twenty":41.971447,"median":65.041128,"eighty":145.824695,"marketCap":56903117},{"date":"2026-02-13","current":42.763361,"twenty":41.971447,"median":63.551106,"eighty":145.824695,"marketCap":61461512},{"date":"2026-02-20","current":42.458474,"twenty":41.971447,"median":63.24105,"eighty":145.493275,"marketCap":61023314},{"date":"2026-02-27","current":53.454201,"twenty":42.254301,"median":62.721688,"eighty":145.079,"marketCap":76826890},{"date":"2026-03-06","current":66.520784,"twenty":42.431782,"median":62.443472,"eighty":144.664725,"marketCap":95606797},{"date":"2026-03-13","current":76.815667,"twenty":42.702384,"median":63.128972,"eighty":143.919031,"marketCap":110403087},{"date":"2026-03-20","current":79.19141,"twenty":42.763361,"median":63.551106,"eighty":143.090481,"marketCap":113817616},{"date":"2026-03-27","current":72.649053,"twenty":42.763361,"median":64.540999,"eighty":142.593352,"marketCap":92906660},{"date":"2026-04-02","current":72.794568,"twenty":42.763361,"median":65.041128,"eighty":142.510497,"marketCap":93092751},{"date":"2026-04-10","current":71.769293,"twenty":42.834982,"median":66.322806,"eighty":142.261933,"marketCap":91781586},{"date":"2026-04-17","current":73.819844,"twenty":42.993249,"median":67.312698,"eighty":141.847658,"marketCap":94403917},{"date":"2026-04-24","current":77.408308,"twenty":43.122362,"median":67.688423,"eighty":141.681948,"marketCap":98992996},{"date":"2026-05-01","current":74.332482,"twenty":43.386324,"median":67.929451,"eighty":140.936253,"marketCap":95059500},{"date":"2026-05-08","current":80.448884,"twenty":43.537662,"median":68.725663,"eighty":139.941994,"marketCap":102881412},{"date":"2026-05-15","current":-99.750333,"twenty":43.537662,"median":68.80861,"eighty":139.113444,"marketCap":80601361},{"date":"2026-05-22","current":-74.812749,"twenty":42.834982,"median":68.518561,"eighty":138.284895,"marketCap":60451020},{"date":"2026-05-29","current":-79.273129,"twenty":42.763361,"median":67.905598,"eighty":137.622056,"marketCap":64055146},{"date":"2026-06-05","current":-81.097832,"twenty":41.971447,"median":67.66819,"eighty":136.959216,"marketCap":65529562},{"date":"2026-06-12","current":-85.963701,"twenty":41.682913,"median":67.11472,"eighty":136.544941,"marketCap":69461335},{"date":"2026-06-18","current":-85.963701,"twenty":40.13099,"median":66.322806,"eighty":136.213522,"marketCap":69461335},{"date":"2026-06-26","current":-78.656787,"twenty":37.052807,"median":65.041128,"eighty":135.799247,"marketCap":63557122},{"date":"2026-07-02","current":-85.963701,"twenty":35.049122,"median":64.353376,"eighty":135.467827,"marketCap":69461335},{"date":"2026-07-10","current":-88.396636,"twenty":34.430006,"median":63.551106,"eighty":134.225003,"marketCap":71427222},{"date":"2026-07-17","current":-86.774679,"twenty":33.882524,"median":63.128972,"eighty":134.225003,"marketCap":70116631},{"date":"2026-07-24","current":-85.98016,"twenty":33.427142,"median":62.443472,"eighty":132.982179,"marketCap":69474635},{"date":"2026-07-31","current":-84.357893,"twenty":32.948871,"median":61.429682,"eighty":132.982179,"marketCap":68163793},{"date":"2026-08-07","current":-90.846963,"twenty":32.464186,"median":60.185471,"eighty":132.982179,"marketCap":73407162},{"date":"2026-08-14","current":-85.98016,"twenty":32.12751,"median":60.185471,"eighty":131.6565,"marketCap":69474635},{"date":"2026-08-21","current":-16.924219,"twenty":31.714084,"median":58.601643,"eighty":127.348043,"marketCap":66845351},{"date":"2026-08-28","current":-16.59569,"twenty":31.190138,"median":58.057586,"eighty":125.359524,"marketCap":65547764}],"updateTime":1788230097872},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"HIT\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2643205436","title":"Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2643205436","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643205436?lang=en_us&edition=fundamental","pubTime":"2026-06-15 20:30","pubTimestamp":1781526600,"startTime":"0","endTime":"0","summary":"New high-value indication for Phase 3-ready asset with data intended to support clinical development and strategic partnering discussionsAdditional billion-dollar target- Cardiac Surgery-Associated Ac","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/15/3311786/0/en/Cadrenal-Therapeutics-Advances-Multi-Indication-Strategy-for-CAD-1005-Launches-Phase-2a-Acute-Kidney-Injury-CSA-AKI-Clinical-Plan-to-Accelerate-Pharma-Partnering-at-Upcoming-BIO-20.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4585","AAQC","BIO","IE00BHPRN162.USD","BK4539","BK4183","BK4007","BK4139","HIT","LENZ","CPB","LU1169590202.USD","CSA","BK4173","ODD","BK4212","LU0149725797.USD","IE0009354923.USD","BK4588","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642235447","title":"Health In Tech Files $300 Million Mixed Shelf Registration","url":"https://stock-news.laohu8.com/highlight/detail?id=2642235447","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642235447?lang=en_us&edition=fundamental","pubTime":"2026-06-12 00:45","pubTimestamp":1781196337,"startTime":"0","endTime":"0","summary":"Health In Tech  Thursday filed a registration statement with the US Securities and Exchange Commission for the potential sale of up to $300 million in securities.The filing covers common stock, preferred stock, warrants, debt securities, subscription rights and units, according to the filing.Proceeds from the offering will be used for general corporate purposes, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7057","HIT","BK4173","HIT.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642235106","title":"Health In Tech files $300M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2642235106","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642235106?lang=en_us&edition=fundamental","pubTime":"2026-06-12 00:25","pubTimestamp":1781195109,"startTime":"0","endTime":"0","summary":"12:24 EDT Health In Tech (HIT) files $300M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving brea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/health-in-tech-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/health-in-tech-files-300m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HIT","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642235616","title":"Health in Tech - May Offer up to $300 Mln in Common Stock, Preferred Stock, Warrants, Debt, Rights, and Units - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2642235616","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642235616?lang=en_us&edition=fundamental","pubTime":"2026-06-12 00:22","pubTimestamp":1781194959,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260611:nFWN42J107:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HIT","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640076399","title":"Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2640076399","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640076399?lang=en_us&edition=fundamental","pubTime":"2026-06-03 21:00","pubTimestamp":1780491600,"startTime":"0","endTime":"0","summary":"Lead asset CAD-1005 being researched for prevention of life-threatening blood clots in patients with Heparin-induced Thrombocytopenia (HIT), targets $2 billion peak annual revenue potential 12-LOX cou","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3306100/0/en/Cadrenal-Therapeutics-to-Showcase-Phase-3-Ready-CAD-1005-and-Novel-12-LOX-Platform-at-BIO-International-Convention-2026-Partnering-Event.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169589451.USD","BK4588","BK4173","BK4539","HIT","BK4121","BK4585","BIO","LU1169590202.USD","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164684664","title":"Yantian International, Chengdu Land Port Company, and HIT Sign Cooperation Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=1164684664","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164684664?lang=en_us&edition=fundamental","pubTime":"2026-05-29 18:41","pubTimestamp":1780051275,"startTime":"0","endTime":"0","summary":"The stable operation of the \"Chengdu-Shenzhen-Hong Kong Fixed-Schedule Train\" represents a concrete practice in deepening logistics coordination and promoting regional interconnected development...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4173","HIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178019222","title":"One-Year Milestone for Chengdu-Shenzhen-Hong Kong Scheduled Rail Service: Fostering Trilateral Synergy and Bolstering the Real Economy","url":"https://stock-news.laohu8.com/highlight/detail?id=1178019222","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1178019222?lang=en_us&edition=fundamental","pubTime":"2026-05-29 07:51","pubTimestamp":1780012301,"startTime":"0","endTime":"0","summary":"A ceremony and client promotion event marking the first anniversary of the inaugural \"Chengdu-Shenzhen-Hong Kong Scheduled Rail Service\" was successfully held in Chengdu. (May 28, Chengdu, China)...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIT","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636864055","title":"Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636864055","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636864055?lang=en_us&edition=fundamental","pubTime":"2026-05-20 04:30","pubTimestamp":1779222600,"startTime":"0","endTime":"0","summary":"PONTE VEDRA, Fla., May  19, 2026  (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and throm","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/19/3297984/0/en/Cadrenal-Therapeutics-to-Participate-in-the-Lytham-Partners-Spring-2026-Investor-Conference-on-May-28-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4173","BK4539","HIT","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635759055","title":"Health In Tech Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635759055","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635759055?lang=en_us&edition=fundamental","pubTime":"2026-05-14 05:47","pubTimestamp":1778708876,"startTime":"0","endTime":"0","summary":"Health In Tech Inc reports results for the quarter ended March 31 - Earnings SummaryHealth In Tech Inc HIT.OQ reported a quarterly adjusted loss of 3 cents per share for the quarter ended March 31, lo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nL8N41Q2Y8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4173","HIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753471","title":"Health In Tech reports Q1 EPS (3c), consensus (2c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753471","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753471?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:09","pubTimestamp":1778702968,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $8.8M, consensus $7.46M. Tim Johnson, Chief Executive Officer of Health In Tech (HIT), commented, “In the first quarter of 2026,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/health-in-tech-reports-q1-eps-3c-consensus-2c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/health-in-tech-reports-q1-eps-3c-consensus-2c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HIT","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635753260","title":"Health In Tech backs FY26 revenue view $45M-$50M, consensus $46.36M","url":"https://stock-news.laohu8.com/highlight/detail?id=2635753260","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635753260?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:06","pubTimestamp":1778702816,"startTime":"0","endTime":"0","summary":"Health In Tech (HIT) reiterated guidance for 2026 annual revenue ranging between $45M-$50M, representing year-over-year growth of approximately 35%...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/health-in-tech-backs-fy26-revenue-view-45m-50m-consensus-46-36m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/health-in-tech-backs-fy26-revenue-view-45m-50m-consensus-46-36m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4173","HIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635675834","title":"Health In Tech Q1 EPS $(0.03), Inline, Sales $4.509M Miss $7.349M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635675834","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635675834?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:01","pubTimestamp":1778702496,"startTime":"0","endTime":"0","summary":"Health In Tech (NASDAQ:HIT) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is a 400 percent decrease over earnings of $0.01 per share from the same period last year.  The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52542458/health-in-tech-q1-eps-0-03-inline-sales-4-509m-miss-7-349m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Health In Tech Q1 EPS $(0.03), Inline, Sales $4.509M Miss $7.349M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIT","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635758656","title":"Health In Tech Q1 FY26 turns to net loss of $1.6 million; revenue rises 9.4% to $8.8 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635758656","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635758656?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:01","pubTimestamp":1778702475,"startTime":"0","endTime":"0","summary":"Health in Tech reported Q1 2026 revenue up 9.4% to $8.8 million.Net results swung to a loss of $1.6 million, or $ per diluted share.Adjusted EBITDA turned to a loss of $1.3 million, reflecting higher sales and marketing expenses tied to long-term growth initiatives.Distribution partners climbed 29.5% to 896, while platform placed plan value totaled $82 million.2026 revenue outlook reiterated at $45 million-$50 million, with contracted revenue for the remaining three quarters at $22.9 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL5Xmdw0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIT","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635939758","title":"Press Release: Health In Tech Reports First Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2635939758","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635939758?lang=en_us&edition=fundamental","pubTime":"2026-05-14 04:00","pubTimestamp":1778702400,"startTime":"0","endTime":"0","summary":"Reiterates Guidance for 2026 Annual Revenue Ranging between $45 Million and $50 Million. STUART, Fla., May 13, 2026 /PRNewswire/ -- Health In Tech, Inc.  , an AI-enabled InsurTech platform company, today announced its unaudited financial results for the three months ended March 31, 2026.-- Revenue increased 9.4% to $8.8 million from $8.0 million in the first. -- Adjusted EBITDA2 totaled $(1.3) million, compared to $1.2 million in the. first quarter of 2025, and reflected higher sales and marketing expenses. -- Cash and cash equivalents totaled $10.3 million, compared to $7.6 million. -- Working capital totaled $15.0 million, compared to $8.8 million as of. The Company expects continued growth driven by expanding engagement across its distribution network and the full deployment of new features launched in January 2026. Unlike the traditional insurance industry, where new product and service implementations typically require one to two years, Health In Tech's AI-driven platform enables ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LU0011850046.USD","LU0417517546.SGD","BK4590","SGXZ23171101.USD","BK4581","LU0971096721.USD","LU0256863811.USD","IE00BQXX3F31.USD","LU2023250504.SGD","LU2237957902.USD","LU0130102774.USD","LU0949170772.SGD","SG9999004303.SGD","SMUP","GB00BDT5M118.USD","LU0648001328.SGD","IE00BQXX3C00.GBP","LU0154245673.USD","LU2237957811.SGD","LU0661504455.SGD","HIT","LU0314106906.USD","BK4144","BK4561","LU1974910355.USD","LU1363072403.SGD","LU0162691827.USD","LU0477156953.USD","LU0130517989.USD","BK4606","LU0738911758.USD","LU0980610538.SGD","LU1201861249.SGD","LU1917777945.USD","LU0390134368.USD","BK4585","BK4182","LU0154245756.USD","LU2023250843.SGD","LU0154236417.USD","BK4112","IE00BQXX3D17.EUR","SMU","LU0124676726.USD","LU1506573853.SGD","LU1153585028.USD","LU0256863902.USD","LU2106854487.HKD","SMZ","LU0689626769.HKD","LU0072461881.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634555022","title":"Health In Tech Inc  expected to post a loss of 3 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634555022","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634555022?lang=en_us&edition=fundamental","pubTime":"2026-05-12 06:10","pubTimestamp":1778537410,"startTime":"0","endTime":"0","summary":"Health In Tech Inc  expected to post a loss of3cents a share - Earnings Preview Health In Tech Inc HIT.OQ HIT.O is expected to  show a fall in quarterly revenue when it reports  results on May 13 for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260511:nL8N41O2RI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4173","HIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633142286","title":"Press Release: Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2633142286","media":"Dow Jones","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633142286?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:30","pubTimestamp":1778157000,"startTime":"0","endTime":"0","summary":"PONTE VEDRA, Fla., May 07, 2026  -- Cadrenal Therapeutics, Inc. , a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the first quarter ended March 31, 2026, and provided a corporate update highlighting continued progress in its CAD-1005 program for HIT. The Company has now received the official minutes from its End-of-Phase 2  meeting with the U.S. Food and Drug Administration , which provided guidance on key elements of the planned pivotal Phase 3 registration trial for CAD-1005, Cadrenal's investigational first-in-class 12-lipoxygenase  inhibitor being developed to treat suspected heparin-induced thrombocytopenia . Based on this feedback and Phase 2 data, Cadrenal plans to advance directly to a randomized, blinded, placebo-controlled Phase 3 study evaluating CAD-1005 added to standard-of-care anticoagulation in patients with HIT.-- Received official FDA EOP2 meeting minutes p","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4173","LABU","BK4007","BK4588","BK6096","HIT","LENZ","BK4585","BK4539","CVKD","BK6505","N0Z.SI","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632647772","title":"Health in Tech AI, marketing chief Dustin Plantholt departs amid business transition","url":"https://stock-news.laohu8.com/highlight/detail?id=2632647772","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632647772?lang=en_us&edition=fundamental","pubTime":"2026-05-02 04:35","pubTimestamp":1777667753,"startTime":"0","endTime":"0","summary":"Health in Tech said Chief AI & Marketing Officer Dustin Plantholt will leave role effective April 30, 2026.HITChain, a Health in Tech subsidiary, signed independent contractor agreement with Plantholt Advisory Group LLC dated May 1, 2026.Consulting agreement allows either party to terminate with 10 days’ written notice.Plantholt will receive 500,000 restricted shares of HITChain common stock, vesting monthly over 12 months subject to continued service.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Health in Tech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 01, 2026, and is so","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nNDL1qm9c7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIT","BK4173"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632085665","title":"Health In Tech to report first-quarter results after market close May 13","url":"https://stock-news.laohu8.com/highlight/detail?id=2632085665","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632085665?lang=en_us&edition=fundamental","pubTime":"2026-05-01 04:08","pubTimestamp":1777579696,"startTime":"0","endTime":"0","summary":"Health In Tech will release first-quarter 2026 financial results on May 13, 2026.Conference call scheduled for May 13, 2026 at 5:00 p.m. ET.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nNDLbqyGhK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4173","HIT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631637932","title":"Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2631637932","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631637932?lang=en_us&edition=fundamental","pubTime":"2026-04-30 20:30","pubTimestamp":1777552200,"startTime":"0","endTime":"0","summary":"FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to stand","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/30/3284867/0/en/Cadrenal-Therapeutics-Announces-End-of-Phase-2-Meeting-with-the-FDA-and-Pivotal-Phase-3-Registration-Path-for-CAD-1005-in-Heparin-Induced-Thrombocytopenia-HIT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HIT","BK4183","BK4139","BK4539","ODD","BK4173","LABU","IE0009354923.USD","LENZ","BK4007","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630282027","title":"Health In Tech files to sell 5.6M shares of Class A common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2630282027","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630282027?lang=en_us&edition=fundamental","pubTime":"2026-04-25 05:10","pubTimestamp":1777065016,"startTime":"0","endTime":"0","summary":"17:08 EDT Health In Tech (HIT) files to sell 5.6M shares of Class A common stock for holders Published first on TheFly – the ultimate source for re...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/health-in-tech-files-to-sell-5-6m-shares-of-class-a-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/health-in-tech-files-to-sell-5-6m-shares-of-class-a-common-stock-for-holders-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4173","HIT"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":65,"code":"91000000","status":"200"}]}}